Tumor necrosis factor beta and soluble APO-1/Fas independently predict progression to AIDS in HIV-seropositive patients

AIDS Res Hum Retroviruses. 1998 Jul 1;14(10):835-43. doi: 10.1089/aid.1998.14.835.

Abstract

The relationship between serum concentration of different components of the nerve growth factor/tumor necrosis factor (TNF) receptor family, including soluble APO-1/Fas (sAPO-1/Fas) and progression of HIV infection, was analyzed in a case-control study of individuals selected from a cohort of HIV-seropositive patients who were progressing or not progressing to AIDS while being treated with nucleoside analogs. HIV-seronegative healthy controls were also analyzed. The results showed that, despite close matching for immunologic (CD4 cell count, beta2-microglobulin concentration) and virologic (p24 antigen, detection of HIV syncytium-inducing phenotype, plasma HIV viremia) parameters, the baseline serum concentrations of TNF-beta and sAPO-1/Fas were statistically different between progressing and nonprogressing patients. In addition, serum concentrations of TNF-beta and sAPO-1/Fas showed the strongest independent predictive power for progression to AIDS in a multivariate conditional logistic regression model. Because TNF-beta and Fas were suggested to be mediators of antigen-induced cell death (AICD) in HIV infection and sAPO-1/Fas was hypothesized to protect lymphocyte against AICD, these data suggest an important pathogenetic role for AICD in the progression of HIV infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / blood
  • Acquired Immunodeficiency Syndrome / immunology
  • Acquired Immunodeficiency Syndrome / physiopathology
  • Acquired Immunodeficiency Syndrome / virology
  • Adult
  • Anti-HIV Agents / therapeutic use
  • Biomarkers / blood
  • CD4 Lymphocyte Count
  • Case-Control Studies
  • Cohort Studies
  • Disease Progression
  • Female
  • HIV Seropositivity / blood*
  • HIV Seropositivity / drug therapy
  • HIV Seropositivity / immunology
  • HIV Seropositivity / virology
  • Humans
  • Lymphotoxin-alpha / blood*
  • Male
  • Predictive Value of Tests
  • Regression Analysis
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Solubility
  • Zidovudine / therapeutic use
  • beta 2-Microglobulin / analysis
  • fas Receptor / blood*

Substances

  • Anti-HIV Agents
  • Biomarkers
  • Lymphotoxin-alpha
  • Reverse Transcriptase Inhibitors
  • beta 2-Microglobulin
  • fas Receptor
  • Zidovudine